ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TXG
BRKR (54) BIO (62) AVTR (56) RVTY (65) ⌘ Pro Terminal →

10x Genomics Inc. (TXG) — RQD Stock Rating Cockpit

$61.63 -12.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $60.17

10x Genomics Inc. (TXG) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $9.13B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TXG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, 10x Genomics Inc. (NASDAQ: TXG) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $61.63 (-12.09% 1D, market cap $9.13B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, TXG ranks #166 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TXG compare to BRKR and BIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), TXG carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 69.1%, and ROIC of -5.7%. By comparison, BRKR (Bruker Corporation) holds a D+ grade (54/100 RQD, P/E N/A, ROIC 1.3%, cap $8.70B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TXG?
▼

Per TXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770787), 10x Genomics Inc. generated $642.8M in revenue (+5.2% YoY), -$43.5M in net income, and $130.1M in free cash flow against $1.04B in total assets and $110.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $60.17 (-2.37%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 20.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510059
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-
Cash (13)Whales (12)SEC (13)Macro (11)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
$108 Bull$62 Base$48 Bear
📬 FREE TXG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TXG)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY TXG SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+13/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 20.2% FCF Margin ($130.1M FCF) & 69.1% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 25.02 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution10/20 pts (-10 pt drag)

Disciplined Float (+0.52% YoY Shares) & executive Form 4 sales trim 10 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$73.10+3.4% Next Q
Q2 (-2Q)
64
Grade C+$75.59+10.6% Next Q
Q3 (-1Q)
62
Grade C+$83.62-26.3% Next Q
Current
59
Grade C-$61.63+0.2% Hist 90D α
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TXG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, TXG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.52% YoY Shares) — any gross margin slip below 66.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($74.96) or 200D SMA ($41.42) invalidates the momentum regime and cuts Target Base ($61.91) toward Bear Floor ($48.29).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TXG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TXG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 59%NO 41%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
45.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
25.02>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE54% OF RANGE
L: $13$61.63H: $103
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (69.1% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on TXG

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

-5.7% ROIC with 69.1% gross margin and 1.22% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 25.02 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (55)

22/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like TXG
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (TXG Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TXG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +184.67%▼ SUPPORT BREAKDOWN
2026-11-03O $81.55H $81.55L $61.63C $61.63VOL 5.22M
RES: $118.7SUP: $71.13SMA50: $74.96SMA200: $41.42
$108.8$83.93$59.04$34.15$9.27RES $118.7SUP $71.13$61.632026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TXG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TXG Butterfly Map → + Track TXG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
17.8%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TXG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TXG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TXG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TXG)

Health Care Rank #166 of 1015 ⚔️ BRKR vs TXG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TXG vs. BRKR, BIO, AVTR, RVTY)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, 10x Genomics Inc. (TXG) ranks #166 by composite RQD confidence (59/100, grade C-) and #119 by equity capitalization ($9.13B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with TXG at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TXG ACTIVE
10x Genomics Inc.
C- 59/100 — 69.1% -5.7% -12.09% $9.13B Benchmark Subject
BRKR
Bruker Corporation
D+ 54/100 — 45.9% 1.3% -2.42% $8.70B /brkr-vs-txg →
BIO
Bio-Rad Laboratories Inc.
C 62/100 13.5x 51.9% 0.5% -1.62% $9.95B /bio-vs-txg →
AVTR
Avantor Inc.
D+ 56/100 — 32.7% -2.1% -2.74% $10.88B /avtr-vs-txg →
RVTY
Revvity Inc.
C 65/100 76.7x — 3.1% -3.44% $17.52B /rvty-vs-txg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001770787 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), 10x Genomics Inc. (TXG) reported GAAP revenue of $642.8M (+5.2% vs. FY2024 revenue of $610.8M , and +3.9% cumulative change since FY2023) , GAAP net income of -$43.5M, operating cash flow of $136.1M, and free cash flow of $130.1M (+2371.2% YoY). On the balance sheet, TXG closed FY2025 with $1.04B in total assets against $110.3M in total debt (Altman Z-Score: 25.02, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $642.8M -$43.5M $136.1M $130.1M $1.04B $110.3M
FY2024 (FY) 2024-12-31 $610.8M -$182.6M $6.7M -$5.7M $918.6M $93.8M
FY2023 (FY) 2023-12-31 $618.7M -$255.1M -$15.2M -$43.0M $5.84B $1.37B

3. TXG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, 10x Genomics Inc. (NASDAQ: TXG) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $61.63 (-12.09% 1D, market cap $9.13B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, TXG ranks #166 in composite RQD confidence.

How does TXG compare to BRKR and BIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), TXG carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of 69.1%, and ROIC of -5.7%. By comparison, BRKR (Bruker Corporation) holds a D+ grade (54/100 RQD, P/E N/A, ROIC 1.3%, cap $8.70B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TXG?

Per TXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770787), 10x Genomics Inc. generated $642.8M in revenue (+5.2% YoY), -$43.5M in net income, and $130.1M in free cash flow against $1.04B in total assets and $110.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TXG trading relative to its 50-day, 200-day, and 52-week technical levels?

TXG last traded at $61.63 (-12.09% on volume of 5,174,635 shares), positioning the stock -17.78% below its 50-day simple moving average ($74.96) and +48.79% above its 200-day simple moving average ($41.42). Across its 52-week range of $12.80 to $102.81, TXG sits at the 54.2% percentile with a 14-day RSI of 45.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($53.93 to $69.33).

Direct Sub-Reports: TXG RQD Cockpit TXG 12M Forecast TXG Earnings & Move TXG Dividends & DRIP TXG Insiders & 13F TXG Whale Options TXG Profit Sankey TXG News & Why
ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

TXG — 10x Genomics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

10x Genomics Inc. (TXG) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $61.63 (-12.09% 1D, market capitalization $9.13B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -5.7%, gross margin of 69.1%, operating margin of -9.5%, and free cash flow yield of 1.22%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (13/20): Incorporates a 1.15x equity beta, Altman Z-Score of 25.02, Piotroski F-Score of 8/9, and Debt/Equity of 0.13x.

2. Business Model, Unit Margins & SEC Financial Trajectory

10x Genomics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry,. The company reported revenue of $642.8M for FY 2025, indicating a revenue-generating operating base. Specific product lines, such as the Atera and Sentira launches referenced in the news wire, are named only as headlines and are not described in detail in the source.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), 10x Genomics Inc. (TXG) reported $642.8M in annual revenue (up from $610.8M in FY2024, +5.2% YoY) and -$43.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($618.7M revenue, -$255.1M net income) through FY2025, TXG scaled operating cash flow to $136.1M and free cash flow to $130.1M, backed by $1.04B in total assets against $110.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C- • RQD 59/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.22% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $12.80 – $102.81 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -9.5% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be established from the provided sources.

  • Key Question #1: Can TXG sustain or expand its -9.5% operating margin and -5.7% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $642.8M and free cash flow of $130.1M, how will capital allocation balance growth reinvestment against $110.3M in total debt?
  • Key Question #3: How sensitive is TXG's 24.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

TXG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for 10x Genomics Inc. (TXG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TXG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TXG Bull vs. Bear Conversation Board — What's Your Call at $61.63?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TXG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TXG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $91.84 (+31.0%)
📌 Pinned Debate

Forensic balance sheet is strong (Altman Z 25.02, Piotroski F 8/9, Debt/Equity 0.13) and FY 2025 free cash flow turned positive at $130

Don't sleep on TXG's setup in Health Care. Forensic balance sheet is strong (Altman Z 25.02, Piotroski F 8/9, Debt/Equity 0.13) and FY 2025 free cash flow turned positive at $130.1M.. Beta of 1.15 means it moves fast when momentum turns, and the 5-pillar RQD gauge (59/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — TXG's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $59.59 (-15.0%)
Spot @ $70.11

ROIC is -5.7%, EPS (TTM) is -0.33, and the operating loss persists at -9.5% margin, so earnings must turn positive to justify the forwa

Sitting on the sidelines or leaning short TXG above $70.11. ROIC is -5.7%, EPS (TTM) is -0.33, and the operating loss persists at -9.5% margin, so earnings must turn positive to justify the forward P/E of 24.. Until Fundamental Cash Engine (13/20) and FCF yield (1.22%) inflect higher, upside is capped near $102.81.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%